Iovance Biotherapeutics, Inc. (LON:0JDK)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 536.75M |
| Revenue (ttm) | 176.29M |
| Net Income (ttm) | -284.60M |
| Shares Out | n/a |
| EPS (ttm) | -0.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 319,441 |
| Average Volume | 161,471 |
| Open | 2.190 |
| Previous Close | 2.210 |
| Day's Range | 2.009 - 2.220 |
| 52-Week Range | 1.570 - 12.425 |
| Beta | 0.83 |
| RSI | 40.68 |
| Earnings Date | Nov 6, 2025 |
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops... [Read more]
Financial Performance
In 2024, Iovance Biotherapeutics's revenue was $164.07 million, an increase of 13698.99% compared to the previous year's $1.19 million. Losses were -$372.18 million, -16.18% less than in 2023.
Financial numbers in USD Financial StatementsNews
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deliveri...
Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health
Key PointsIovance Biotherapeutics and Teladoc Health have both sharply lagged the market.
Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play
Iovance Biotherapeutics (IOVA) maintains a Buy rating, supported by growing Amtagvi sales, promising efficacy data, and ongoing label expansion opportunities. IOVA's restructuring aims to cut over $10...
IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options If you are a long-term stoc...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deliver...
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...
Why Iovance Biotherapeutics Stock Got Mashed on Monday
The company announced a flotation of its common shares that is potentially quite dilutive.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deliveri...
Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25
IOVA's Q2'25 progress boosts confidence with Amtagvi growth & restructuring. Upcoming trial data & Canada launch may drive stock upside.
Why Iovance Biotherapeutics Stock Was Climbing Today
One and a half years after getting the nod from the U.S. Food and Drug Administration, its Amtagvi moves forward in a neighboring country.
Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma
First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy
Why Iovance Biotherapeutics Stock Plummeted Today
The company's top line nearly doubled.
Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript
Iovance (IOVA) Q2 Revenue Jumps 93%
Iovance Biotherapeutics GAAP EPS of -$0.33 misses by $0.04, revenue of $60M misses by $7.14M
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025
$60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reite...
Is Iovance Biotherapeutics Stock Due for a Big Rally?
The biotech stock has been picking up steam of late -- but will it last?
Iovance Biotherapeutics Is Waking Up - Price Action Screams Breakout, But Fundamentals Demand Patience
Here's why Iova stock surged 32% today and why the rally might not be over
Iova stock rallied 32% on Wednesday, snapping out of a long, sluggish stretch that had frustrated investors for months. The Iovance Biotherapeutics (NASDAQ: IOVA) shares have been stuck in a tight ran...
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of GE Vernova Inc . (NYSE: GEV) rose sharply during Wednesday's session after the company posted bette...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deliveri...
Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug
Iovance Biotherapeutics, Inc. stock faces challenges with disappointing Q1 earnings & competition. Click for why potential 2025 success could revive IOVA valuation.
IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
SAN CARLOS, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona...
Levi & Korsinsky Reminds Iovance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 – IOVA
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit.